Drug developed for Type 2 diabetes helps control Type 1 diabetes

UB endocrinologists who in recent years found that patients with Type 1 diabetes benefit from insulin plus a drug designed for Type 2 diabetes, have now found that they also can benefit from dapagliflozin, another drug designed and marketed to treat Type 2 diabetes. Researchers at the Jacobs School of Medicine and Biomedical Sciences on Aug. 4 published a paper online ahead of print in the Journal of Clinical Endocrinology and Metabolism that reports that patients with Type 1 diabetes saw improved blood glucose control with a “triple therapy” that included insulin, liraglutide and dapagliflozin.

Start the conversation, or Read more at Science Blog.